


FIGURE 1

	Tumor Volume			
	Saline Infusion	Saline PRVI	SD-101 Infusion	SD-101 PRVI
	135.892224	55.67284	39.16125	328.33751
	1143.23323	128.505488	584.583168	19.20996
	98.97316	158.682636	86.8900175	0.01875
	197.308272	281.57625	1778.87162	
	17.075591	281.57625	254.0664	
	151.381696		855.8664	
	169.885156		135.210384	
	647.224512		362.905613	
	255.102801		430.563328	
	366.235506		249.716448	
	1146.12505		116.067848	
	209.776248		32.8763655	
Mean	378.184454	181.202693	410.564903	115.855407
SEM	113.005648	44.2671404	143.066465	106.385398

FIGURE 2A




FIGURE 2B

	Tumor Weight			
	Saline Infusion	Saline PRVI	SD-101 Infusion	SD-101 PRVI
	0.52	0.32	0.41	0.44
	0.87	0.37	0.62	0.29
	0.39	0.26	0.34	0.08
	0.79	1.24	1.24	
	0.17	0.66	0.66	
	0.38	0.65	0.65	
	0.34	0.63	0.28	
	0.59	0.63	0.42	
	0.46		0.35	
	0.71		0.5	
	0.62		0.53	
	0.28		0.2	
Mean	0.51	0.595	0.51666667	0.27
SEM	0.0614102	0.10890691	0.07827045	0.10440307

FIGURE 3A




FIGURE 3B



Normalized Labeled SD-101 Signal Intensity in Pancreas
(all data)
Normalized Signal Intensity
22
20
18
16
14
12
10
8
6
4
2
0
**p=0.000
Signal in Non-Target Tissue
Signal in Target Tissue

FIGURE 4



Normalized Labeled SD-101 Signal Intensity in Pancreas
(outlier removed)
Normalized Signal Intensity
20
18
16
14
12
10
8
6
4
2
0
**p=0.000
Signal in Non-Target Tissue
Signal in Target Tissue

FIGURE 5



Treated Tissue Volume
Tissue Volume (cm³)
10
9
8
7
6
5
4
3
2
1
0
p=0.010
PRVI Endhole
PRVI SEAL

FIGURE 6



Signal Intensity of Labeled SD-101
Signal Intensity (lu)
5000
4500
4000
3500
3000
2500
2000
1500
1000
500
0
p=0.025
PRVI Endhole
PRVI SEAL

FIGURE 7



Treated Tissue Volume
Tissue Volume (cm³)
10
9
8
7
6
5
4
3
2
1
0
p=0.007
PRVI Endhole
PRVI SEAL

FIGURE 8



Signal Intensity of Labeled SD-101
Signal Intensity (lu)
5000
4500
4000
3500
3000
2500
2000
1500
1000
500
0
p=0.019
PRVI Endhole
PRVI SEAL

FIGURE 9




FIGURE 10A




FIGURE 10B



PHASE 1
SINGLE AGENT SD-101 PRVI/PEDD DOSE ESCALATION
PHASE 1b
SD-101 PRVI/PEDD DOSE ESCALATION + SYSTEMIC CHECKPOINT INHIBITION
SD-101 4 mg (n=3 – 6)
SD-101 2 mg (n=3 – 6)
SD-101 0.5 mg (n=3 – 6)
SD-101 SINGLE AGENT RP2D EXPANSION (n=10, optional)
SD-101 RP2D + Pembro (n=3 – 6)
SD-101 RP2D-1 + Pembro (n=3 – 6)
OPTIONAL COHORT WITH SD-101 RP2D + NIVO/IPI
OPTIONAL EXPANSION COHORT WITH RP2 REGIMEN (N=10)

FIGURE 11